Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo
JA Morales-Garcia, R Luna-Medina… - ACS chemical …, 2012 - ACS Publications
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase originally identified as a
regulator of glycogen metabolism but it also plays a pivotal role in numerous cellular …
regulator of glycogen metabolism but it also plays a pivotal role in numerous cellular …
Peripheral administration of GSK-3β antisense oligonucleotide improves learning and memory in SAMP8 and Tg2576 mouse models of Alzheimer's disease
SA Farr, KE Sandoval, ML Niehoff… - Journal of …, 2016 - content.iospress.com
Abstract Glycogen synthase kinase (GSK)-3β is a multifunctional protein that has been
implicated in the pathological characteristics of Alzheimer's disease (AD), including the …
implicated in the pathological characteristics of Alzheimer's disease (AD), including the …
The selective and competitive N-methyl-D-aspartate receptor antagonist,(−)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid, prevents synaptic toxicity …
The toxicity of amyloid β (Aβ) is highly associated with Alzheimer's disease (AD), which has
a high incidence in elderly people worldwide. While the current treatment for moderate and …
a high incidence in elderly people worldwide. While the current treatment for moderate and …
A novel glycogen synthase kinase‐3 inhibitor 2‐methyl‐5‐(3‐{4‐[(S )‐methylsulfinyl]phenyl}‐1‐benzofuran‐5‐yl)‐1,3,4‐oxadiazole decreases tau phosphorylation …
T Onishi, H Iwashita, Y Uno, J Kunitomo… - Journal of …, 2011 - Wiley Online Library
J. Neurochem.(2011) 10.1111/j. 1471‐4159.2011. 07532. x Abstract Alzheimer's disease
(AD) is a neurodegenerative disorder leading to a progressive loss of cognitive function and …
(AD) is a neurodegenerative disorder leading to a progressive loss of cognitive function and …
Amyloid beta 1-42 inhibits entorhinal cortex activity in the beta-gamma range: role of GSK-3
F Pena-Ortega, A Solis-Cisneros… - Current Alzheimer …, 2012 - ingentaconnect.com
Oscillatory activity in the entorhinal cortex has been associated with several cognitive
functions. Accordingly, Alzheimer Disease-associated cognitive decline has been related to …
functions. Accordingly, Alzheimer Disease-associated cognitive decline has been related to …
Metabotropic NMDA receptor function is required for β-amyloid–induced synaptic depression
HW Kessels, S Nabavi… - Proceedings of the …, 2013 - National Acad Sciences
The mechanisms by which β-amyloid (Aβ), a peptide fragment believed to contribute to
Alzheimer's disease, leads to synaptic deficits are not known. Here we find that elevated …
Alzheimer's disease, leads to synaptic deficits are not known. Here we find that elevated …
Amyloid beta peptide 1–42 disturbs intracellular calcium homeostasis through activation of GluN2B-containing N-methyl-d-aspartate receptors in cortical cultures
IL Ferreira, LM Bajouco, SI Mota, YP Auberson… - Cell calcium, 2012 - Elsevier
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that leads to
debilitating cognitive deficits. Recent evidence demonstrates that glutamate receptors are …
debilitating cognitive deficits. Recent evidence demonstrates that glutamate receptors are …
Amyloid β/PKC-dependent alterations in NMDA receptor composition are detected in early stages of Alzheimer´ s disease
C Ortiz-Sanz, U Balantzategi, T Quintela-López… - Cell Death & …, 2022 - nature.com
Amyloid beta (Aβ)-mediated synapse dysfunction is an early event in Alzheimer's disease
(AD) pathogenesis and previous studies suggest that NMDA receptor (NMDAR) …
(AD) pathogenesis and previous studies suggest that NMDA receptor (NMDAR) …
Amyloid beta-mediated changes in synaptic function and spine number of neocortical neurons depend on NMDA receptors
MK Back, S Ruggieri, E Jacobi… - International Journal of …, 2021 - mdpi.com
Onset and progression of Alzheimer's disease (AD) pathophysiology differs between brain
regions. The neocortex, for example, is a brain region that is affected very early during AD …
regions. The neocortex, for example, is a brain region that is affected very early during AD …
Glycogen synthase kinase 3: a drug target for CNS therapies
RV Bhat, SL Budd Haeberlein… - Journal of …, 2004 - Wiley Online Library
Abstract Glycogen synthase kinase3 (GSK3) is emerging as a prominent drug target in the
CNS. The most exciting of the possibilities of GSK3 lies within the treatment of Alzheimer's …
CNS. The most exciting of the possibilities of GSK3 lies within the treatment of Alzheimer's …